Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Projected to Reach $3.33 Billion by 2029 at a CAGR of 11%
Discover trends, market shifts, and competitive outlooks for the chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
What Are the Key Projections for the CAGR of the Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Size From 2025 to 2034?
The market size for testing chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) has experienced a swift expansion in the past few years. Its growth is anticipated to surge from $1.98 billion in 2024 to $2.2 billion in 2025, boasting a compound annual growth rate (CAGR) of 11.1%. Factors such as the rise in antibiotic resistance, increased awareness campaigns and education, and changes in policy have contributed to its growth in the historic period.
The market size for testing Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) is set for significant expansion in the coming years. It is projected to soar to $3.33 billion by 2029, reflecting a compound annual growth rate (CAGR) of 10.9%. This momentum during the projection period can be associated with the rise of telemedicine and telehealth, the emergence of personalized medicine practices, the development of point-of-care testing, and the implementation of population health management strategies. The major current trends include the growth of rapid point-of-care testing, personalization of testing methods, platforms for testing multiple diseases, as well as the development of community-based testing and outreach programs.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14667&type=smp
What are the Fundamental Drivers and Innovations Shaping the Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market?
The surge in sexually transmitted infections (STIs) is set to fuel the expansion of the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market. STIs are diseases triggered by bacteria, viruses, or parasites, which are passed on through sexual contact. The climb in STI instances can be attributed to the insufficient sex education, increased sexual activities, stigma, and numerous hurdles. CT and NG testing are implemented to identify and manage STIs, thereby facilitating early diagnosis, management, and avoiding transference. For instance, the World Health Organization, Switzerland, reported in July 2023, that over a million STIs are contracted daily around the world, with an annual estimate of 374 million new infections occurring, of which one of four is treatable. As such, the escalating numbers of STIs are stimulating the growth of the CTNG testing market.
How Is the Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Segmented?
The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market covered in this report is segmented –
1) By Test Type: Laboratory, Point Of Care Testing
2) By Product: Assays And Kits, Instruments Or Analyzers
3) By Technology: Isothermal Nucleic Acid Amplification Technology, Polymerase Chain Reaction, Immunodiagnostics, Other Technologies
4) By End User: Diagnostic Laboratories, Hospitals And Clinics, Other End Users
Subsegments:
1) By Laboratory: Nucleic Acid Amplification Tests (NAAT), Polymerase Chain Reaction (PCR) Tests, Enzyme-Linked Immunosorbent Assay (ELISA), Immunofluorescence Assay (IFA), Culture Tests, Direct Fluorescent Antibody (DFA) Tests
2) By Point Of Care Testing: Rapid Diagnostic Tests (RDT), Lateral Flow Assays, Immunochromatographic Tests, Self-Testing Kits, Loop-Mediated Isothermal Amplification (LAMP), Microfluidics-Based Tests
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=14667&type=smp
Which Regions Are Driving the Next Phase of the Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Growth?
North America was the largest region in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market in 2024. The regions covered in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Key Trends Are Shaping the Future of the Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market?
Leading corporations in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing industry are directing their efforts towards the creation of novel screening solutions like the BD COR MX/PX System. This advanced, high-throughput infectious disease molecular diagnostic platform has been designed to meet the urgent requirement for precise, effective, and scalable testing methodologies in the face of rising sexually transmitted infections. The BD COR MX/PX System, being a state-of-the-art laboratory system, is capable of rapidly and effectively analysing a multitude of samples for infectious agents. For example, in May 2022, Becton Dickinson and Company, a medical device firm based in the US, introduced its novel, fully automated, high-throughput infectious disease molecular diagnostics platform, the BD COR MX/PX System designed to improve workflow efficiency in laboratories processing numerous infectious disease tests such as chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing. The entire process is automated using robotics and software algorithms, from sample receipt to result delivery, enhancing efficiency and potentially shortening the waiting period for test outcomes. Moreover, it offers automation, high-throughput ability, dual DNA targets, and a modular and scalable design.
View the full report here:
How Is the Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Defined and What Are Its Core Parameters?
Chlamydia trachomatis (CT) and Neisseria gonorrhea (NG) testing refers to the procedure for diagnosing sexually transmitted infections (STIs) brought on by neisseria gonorrhea (NG) and chlamydia trachomatis (CT) within sexually active individuals, especially if they have multiple partners or engage in unprotected sexual activity. These tests are conducted to detect the presence of these bacteria in individuals, typically through methods such as urine samples, swabs of genital areas, or blood tests.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=14667
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
